



# Metabolic and vascular effects of silybin in hypertensive patients with high 1-h post-load plasma glucose

Angela Sciacqua<sup>1</sup> · Maria Perticone<sup>2</sup> · Giovanni Tripepi<sup>3</sup> · Desire Addesi<sup>4</sup> · Velia Cassano<sup>1</sup> · Raffaele Maio<sup>1</sup> · Giorgio Sesti<sup>1</sup> · Francesco Perticone<sup>1</sup>

Received: 4 August 2018 / Accepted: 13 September 2018 / Published online: 19 September 2018  
© Società Italiana di Medicina Interna 2018

## Abstract

Hypertensive patients with normal glucose tolerance (NGT) but 1-h post-load plasma glucose  $\geq 155$  mg/dl (1-h high), during an oral glucose tolerance test (OGTT), show higher insulin resistance and multiple target organ damages. Experimental and clinical studies demonstrate that silybin presents anti-inflammatory and metabolic effects, improving insulin resistance and endothelial dysfunction. This study aims to evaluate the effects of the complex silybin–vitamin E and phospholipids on inflammatory, metabolic and vascular parameters in NGT 1-h high hypertensive patients. This is a pilot, single arm, interventional, longitudinal study enrolling 50 Caucasian NGT 1-h high hypertensive outpatients, 27 men and 23 women, age range 42–60 years (mean + SD =  $52 \pm 7$ ). After 6 months of silybin intake, there is a significant improvement in metabolic profile. The glucose response during OGTT significantly improves (AUC<sub>glucose</sub><sub>0–120</sub>  $309.6 \pm 63.4$  at baseline vs  $254.6 \pm 35.5$  at the follow-up,  $\Delta = -55$ , 95% CI from  $-67$  to  $-43$ ,  $p < 0.0001$ ), so as insulin response (AUC<sub>insulin</sub><sub>0–120</sub>  $238.2 \pm 99.1$  vs  $159.3 \pm 44.9$ ,  $\Delta = -78.9$ , 95% CI from  $-100.0$  to  $-57.8$ ,  $p < 0.0001$ ), in accordance with the increase of insulin sensitivity index Matsuda. Silybin intake is associated with a significant reduction of both clinical and central systolic blood pressure, with betterment in clinical and central pulse pressure and reduction of arterial stiffness parameters. In conclusion, this study demonstrates that silybin may improve the metabolic aspect and vascular damage in NGT 1-h high hypertensive patients who are at higher metabolic and cardiovascular risk. Thus, in these patients, silybin might strengthen the effect of antihypertensive drugs giving further cardiovascular protection.

**Keywords** Silybin · Essential hypertension · Insulin resistance · Vascular damage

---

Angela Sciacqua and Maria Perticone contributed equally to the work.

---

✉ Angela Sciacqua  
sciacqua@unicz.it

- <sup>1</sup> Department of Medical and Surgical Sciences, University Magna Graecia of Catanzaro, Campus Universitario di Germaneto, V.le Europa, 88100 Catanzaro, Italy
- <sup>2</sup> Department of Experimental and Clinical Medicine, University Magna Graecia of Catanzaro, Catanzaro, Italy
- <sup>3</sup> CNR-IFC, Istituto di Fisiologia Clinica, Clinical Epidemiology and Physiopathology of Renal Diseases and Hypertension, Reggio Calabria, Italy
- <sup>4</sup> Internal Medicine Unit, Pugliese-Ciaccio Hospital, Catanzaro, Italy

## Introduction

Insulin resistance (IR) represents a common pathophysiological mechanism of type 2 diabetes and arterial hypertension, both associated with the appearance and progression of cardiovascular disease (CVD) [1, 2].

Recently, we reported that a value of 1-h post-load plasma glucose  $\geq 155$  mg/dL (1-h high), during an oral glucose tolerance test (OGTT), is able to identify subjects with normal glucose tolerance (NGT) but who are at high risk of incident type 2 diabetes [3]; in accordance with this, 1-h high NGT hypertensive patients show an unfavorable metabolic profile characterized by higher IR and subclinical inflammation and multiple target organ damages, similar to that observed in individuals with impaired glucose tolerance (IGT) [4–8].

Experimental and clinical studies demonstrate that silybin, the main active component extracted from the milk thistle, presents important anti-inflammatory, antifibrotic and

metabolic effects, particularly, in the liver [9, 10]. In patients with non-alcoholic fatty liver disease (NAFLD), the complex silybin–vitamin E-phospholipids may improve all metabolic syndrome parameters, reducing IR and ameliorating glucose metabolism and liver histology [11, 12]. Given the common pathophysiological pathways shared by both cardiovascular and metabolic diseases, it is plausible that silybin may be protective also for tissues other than the liver, and in different clinical settings. Thus, silybin shows markedly improved IR and endothelial dysfunction in an animal model of diabetes and obesity [13]. On the basis of these considerations, the aim of this study is to evaluate the effects of the complex silybin–vitamin E and phospholipids (<sup>®</sup>Realsil) on inflammatory, metabolic and vascular parameters in a group of never-treated 1-h high NGT hypertensive patients.

## Methods

### Study population

This pilot, single arm, interventional, longitudinal study consists of 50 Caucasian never-treated hypertensive outpatients, 27 men and 23 women, age range 42–60 years (mean + SD = 52 ± 7), who have an NGT with 1-h post-load plasma glucose  $\geq$  155 mg/dl, during OGTT. All patients underwent physical examination and review of their medical history. Causes of secondary hypertension were excluded by appropriate clinical and biochemical tests. Other exclusion criteria were represented by history or clinical evidence of ischemic or valvular heart disease, congestive heart failure, peripheral vascular and chronic gastrointestinal diseases associated with malabsorption, chronic pancreatitis, history of any malignant or autoimmune disease, alcohol or drug abuse, liver or kidney failure, treatments able to modify glucose metabolism and smoking.

All subjects underwent anthropometrical evaluation by measuring weight, height, body mass index (BMI) and waist. After 12-h fasting, a 75 g OGTT was performed with 0, 30-, 60-, 90- and 120-min sampling for plasma glucose and insulin. Glucose tolerance status was defined on the basis of OGTT using the World Health Organization (WHO) criteria.

### Laboratory determinations

Glucose, triglyceride, total and high density lipoprotein cholesterol (HDL-C) concentrations were determined by enzymatic methods (Roche, Basel, Switzerland). Plasma insulin concentration was determined with a chemiluminescence-based assay (Immulite, Siemens, Italy). The minimum detectable concentration was 2 mIU/mL and the maximal inter-assay coefficient of variation was 5.5%. Total serum insulin like growth factor (IGF)-1 concentrations were

measured by a chemiluminescent immunoassay (Nichols Institute Diagnostic, San Juan Capistrano, CA). The minimum detectable concentration was 0.03 mg/l, and the maximal inter-assay coefficient of variation was 7%. Alanine aminotransferase (ALT) and aspartate aminotransferase (AST) levels were measured using the  $\alpha$ -ketoglutarate reaction, and high-sensitivity C-reactive protein (hs-CRP) was measured by automated instrument (CardioPhase\_hs-CRP, Siemens, Italy). The intra-assay coefficient of variation for hs-CRP was < 6%. Serum creatinine and uric acid (UA) were measured in the routine laboratory by an automated technique based on the measurement of Jaffe chromogen and by the URICASE/POD (Boehringer Mannheim, Mannheim, Germany) method implemented in an autoanalyzer.

### Insulin sensitivity

The homeostasis model assessment (HOMA) index was calculated as [fasting insulin ( $\mu$ U/mL)  $\times$  fasting glucose (mmol/l)]/22.5. Insulin sensitivity was evaluated using the Matsuda index (insulin sensitivity index [ISI]), calculated as follows:  $10,000/\text{square root of} [\text{fasting glucose (mmol/l)} \times \text{fasting insulin (mU/l)}] \times [\text{mean glucose} \times \text{mean insulin during OGTT}]$ . The Matsuda index is strongly related to euglycemic–hyperinsulinemic clamp, which represents the gold standard test for measuring insulin sensitivity [14, 15]. The trapezoidal method was used to calculate glucose and insulin area under the curve (AUC) during the OGTT [16]. Renal function was evaluated by calculation of the estimated glomerular filtration rate (e-GFR), using the CKD-Epi equation [17].

### Blood pressure measurements

Readings of clinic blood pressure (BP) were obtained in the left arm of the supine patients, after 5 min of quiet rest, with a mercury sphygmomanometer. Systolic BP (SBP) and diastolic BP (DBP) were recorded at the first appearance (phase I) and the disappearance (phase V) of Korotkoff sounds. Baseline BP values were the average of the last two of the three consecutive measurements obtained at intervals of 3 min, on three separate occasions at least 2 weeks apart. Patients with a clinic SBP  $\geq$  140 mmHg or DBP  $\geq$  90 mmHg were defined as hypertensive, according to current guidelines [18]. For the study protocol, only patients with essential arterial hypertension of mild degree were considered (SBP  $\geq$  140 mmHg and < 160 mmHg and/or DBP  $\geq$  90 and < 100 mmHg).

### Arterial stiffness and central BP measurements

The evaluation of the arterial stiffness was performed by the analysis of the shape and speed of the peripheral and

central pressure wave. All studies were performed in the supine position, in a quiet room with a constant temperature between 22 and 24 °C, after abstaining from cigarette smoking and food and alcohol intake in the 12 h preceding the study. These measurements were obtained by a validated system (SphygmocorTM; AtCor Medical, Sydney, Australia) that employs high-fidelity applanation tonometry (Millar) and appropriate computer software for the analysis of pressure wave (SphygmocorTM) [6]. Pressure calibration was obtained through automatically, non-invasively recorded supine brachial artery BP of the dominant arm after a 30-min rest (Dinamap Compact T; Johnson & Johnson Medical Ltd, Newport, UK). BP was measured five times over 10 min, and the mean of the last three measurements was taken for calibration. Pressure wave recording was performed at the radial artery of the dominant arm with the wrist softly hyperextended, and it is the average of single pressure waves recorded consecutively for 8 s. Pressure wave recordings were accepted only if variation of peak and bottom pressures of single pressure waves was < 5%. The central pressure wave was automatically derived from the radial pressures by a built-in generalized transfer function. In addition, pressure wave measurement was also obtained at the right carotid artery, as it is well known that central AI may be more accurately derived from this vascular site [19]. Central waveforms were further analyzed to identify the time to peak/shoulder of the first (T1) and second (T2) pressure wave components during systole. The pressure at the peak/shoulder of T1 was identified as outgoing pressure wave height (P1), and the pressure at the peak/shoulder of T2 was identified as the reflected pressure wave height (P2), either absolutely or as percent of ejection duration. AP was defined as the difference between P2 and P1, and AI as  $[AP/pulse\ pressure\ (PP)] \times 100$ . Aortic pulse wave velocity (PWV) was determined from the carotid and femoral pressure waveforms. Carotid to femoral transit time (DT) was computed from the foot-to-foot time difference between carotid and femoral waveforms. The distance between the surface markings of the sternal notch and femoral artery was used to estimate the path length between the carotid and femoral arteries (L), and PWV was computed as  $L/DT$ .

### Modality of intervention

After enrollment, all patients were encouraged to make lifestyle changes according to the current guidelines [20]; moreover, it was also recommended to take silybin conjugated to vitamin E and phosphatidylcholine that shows higher intestinal absorption and bioavailability (Indena, IBI-Lorenzini spa Italy: Realsil®) as granules for oral solution at a dose of 3 g bid. Each subject was re-evaluated monthly by performing a clinical examination to consider the necessity for antihypertensive treatment. Finally, inflammatory, metabolic and

hemodynamic parameters were assessed after 6 months of treatment. In particular, at the end of the follow-up period, a new OGTT was performed, to test the effects of silybin on glucose tolerance and IR status.

The protocol was approved by the local Ethics Committee (Comitato Etico Azienda Ospedaliera “Mater Domini”) and informed written consent was obtained from all participants. All the investigations were performed in accordance with the principles of the 1975 Declaration of Helsinki (clinicaltrials.gov: NCT03538327).

### Statistical analysis

Continuous data are expressed as mean  $\pm$  SD. For all variables, comparisons between baseline ( $T_0$ ) and post-treatment values ( $T_6$ ) were performed using paired Student’s *t* test. The changes in all biomarkers in response to silybin intake were expressed as mean and 95% CI, according to the CONSORT statement [21]. Simple linear regression analysis was performed to assess the relationship between variation in arterial stiffness indices (PWV, AI, AP), expressed as  $\Delta$  of variation between baseline and follow-up ( $\Delta_{T_0-6}$ ) and the variation of metabolic and inflammatory covariates that significantly improved after the treatment (expressed as  $\Delta_{T_0-6}$ ). Thus, variables reaching statistical significance and gender, as dichotomic variable, were inserted in a stepwise multivariate linear regression model to assess the magnitude of their individual effect on  $\Delta$ PWV,  $\Delta$ AI and  $\Delta$ AP, with regard to the relationship of a variable every eight patients.

In the regression analysis, to test the independent effect of glucose and insulin responses on vascular parameters, we included only  $\Delta AUC_{0-120}$  of glucose and insulin. We did not include  $\Delta$ Matsuda to avoid a possible colinearity. Differences were assumed to be significant at  $p < 0.05$ . All comparisons were performed using SPSS 20.0 statistical software for Windows (SPSS, Inc., Chicago, IL).

## Results


### Study population

The main clinical, anthropometric and biochemical parameters of the study population at baseline and after the period of treatment are reported in Table 1. After 6 months of silybin intake, there is a significant improvement in metabolic profile; in particular, a significant reduction in total cholesterol and triglyceride and an increase in HDL-cholesterol levels are observed. In addition, fasting glucose and insulin significantly decrease after silybin treatment with reduction of the HOMA index. Of interest, as shown in Fig. 1, the glucose response during OGTT is significantly reduced after silybin ( $AUC_{glucose_{0-120}} 309.6 \pm 63.4$

**Table 1** Anthropometric and biochemical characteristics of the study population before and after 6 months of treatment with silybin

Variables	Baseline	After silybin	Follow-up—baseline (mean change and 95% CI)	<i>p</i>
Gender, <i>M</i> (%)	27(54.0)			
BMI, kg/m <sup>2</sup>	30.8±4.3	30.1±4.1	− 0.8 (− 2.2 to 0.5)	0.223
Waist, cm	101.8±11.6	101.1±10.5	− 0.7 (− 3.9 to 2.4)	0.623
Fasting glucose, mg/dl	99.5±11.1	95.6±9.7	− 0.2 (− 0.30 to − 0.13)	<0.0001
Fasting insulin, μU/ml	18.6±9.3	14.8±7.2	− 4.0 (− 4.9 to − 3.0)	<0.0001
HOMA	4.8±2.8	3.6±1.9	− 1.2 (− 1.5 to 0.9)	<0.0001
Matsuda/ISI	42.8±23.2	60.3±25.6	17.6 (15.6 to 19.6)	<0.0001
IGF-1, ng/ml	122.1±39.9	135.1±46.2	13.1 (5.9 to 20.3)	0.001
Total cholesterol, mg/dl	215.7±29.1	205.6±19.2	− 9.3 (− 14.3 to − 4.2)	<0.0001
HDL-cholesterol, mg/dl	45.1±9.7	48.1±10.3	2.9 (1.2 to 4.6)	0.001
Triglyceride, mg/dl	172.6±65.6	142.9±44.3	− 29.6 (− 39.3 to − 17.7)	<0.0001
Creatinine, mg/dl	0.85±0.15	0.81±0.15	− 0.04 (− 0.08 to − 0.01)	0.006
e-GFR, ml/min/1.73 m <sup>2</sup>	103.1±26.4	101.6±24.3	4.0 (0.9 to 7.2)	0.013
Uric acid, mg/dL	5.7±1.6	5.2±1.4	− 0.5 (− 0.8 to − 0.2)	0.001
hs-CRP, mg/L	4.6±2.9	3.3±1.8	− 1.3 (− 1.7 to − 0.8)	<0.0001
AST, UI/L	26.7±11.9	24.7±7.9	− 2.0 (− 3.5 to − 0.6)	0.007
ALT, UI/L	33.5±16.9	32.1±14.6	− 1.7 (− 3.1 to 0.3)	0.035

*BM* body mass index, *HOMA* homeostatic model assessment, *ISI* insulin sensitivity index, *IGF-1* insulin like growth factor 1, *e-GFR* estimated glomerular filtration rate, *hs-CRP* high-sensitivity C-reactive protein



**Fig. 1** Glucose (on the left) and insulin (on the right) response, expressed as area under the curve (AUC), during the oral glucose tolerance test (OGTT), at baseline and after silybin treatment. Both

AUC for glucose<sub>0–120</sub> and AUC for insulin<sub>0–120</sub> are significantly improved after 6 months of silybin intake

vs  $254.6 \pm 35.5$ ,  $\Delta = -55$ , 95% CI from  $-67$  to  $-43$ ,  $p < 0.0001$ ), as well as insulin response (AUC<sub>insulin</sub><sub>0–120</sub>  $238.2 \pm 99.1$  vs  $159.3 \pm 44.9$ ,  $\Delta = -78.9$ , 95% CI from  $-100.0$  to  $-57.8$ ,  $p < 0.0001$ ); in accordance with this, the Matsuda index significantly increases (Table 1). In addition, silybin treatment is associated with an increase in IGF-1 levels, and the improvement of renal function is demonstrated by a significant increase of  $4 \text{ ml/min/1.73 m}^2$  in e-GFR. Finally, also hs-CRP, UA and liver enzymes are significantly reduced by silybin treatment, confirming a

general improvement of both metabolic and inflammatory status, without any significant change in the anthropometric parameters.

In Table 2, we report the clinical and central hemodynamic parameters, before and after silybin treatment. Interestingly, silybin intake is significantly associated with a reduction of both clinical and central SBP, with consequent betterment in clinical and central PP values. Similarly, we observed a significant reduction in PWV and the other related arterial stiffness parameters, i.e., AI and AP.

**Table 2** Peripheral and central hemodynamic parameters of the study population before and after 6 months of silybin treatment

Variables	Baseline	After silybin	Follow-up—baseline (mean change and 95% CI)	<i>p</i>
Clinical SBP, mmHg	145.3±7.2	135.3±8.6	− 10.1 (− 13.3 to − 6.9)	<0.0001
Clinical DBP, mmHg	82.9±9.1	80.8±9.1	− 2.2 (− 4.6 to 0.3)	0.086
Clinical PP, mmHg	63.4±8.9	54.4±7.3	− 7.9 (− 10.1 to − 5.8)	<0.0001
c-SBP, mmHg	133.6±6.3	124.9±7.8	− 8.8 (− 11 to − 6.5)	<0.0001
c-DBP, mmHg	71.1±8.2	70.7±8.7	− 0.3 (− 1.6 to 1.0)	0.525
c-PP, mmHg	62.5±10.8	54.2±8.8	− 8.4 (− 10.8 to − 6.1)	<0.0001
AP, mmHg	14.8±8.5	12.4±6.9	− 2.4 (− 3.2 to − 1.6)	<0.0001
AI, %	21.4±9.1	15.8±7.2	− 5.5 (− 6.2 to − 4.7)	<0.0001
PWV, m/s	6.9±2.1	5.9±1.7	− 1.0 (− 1.4 to − 0.6)	<0.0001

SBP systolic blood pressure, DBP diastolic blood pressure, PP pulse pressure, c central, AP augmentation pressure, AI augmentation index, PWV pulse wave velocity

### Correlational analysis on arterial stiffness parameters

A linear regression analysis was performed to test the correlation between change in arterial stiffness indices (PWV, AI, AP), expressed as  $\Delta$  of variation between baseline and follow-up ( $\Delta_{T0-6}$ ) and the different metabolic and inflammatory covariates. As shown in Table 3,  $\Delta$ PWV is significantly correlated with  $\Delta$ AUC insulin<sub>0-120</sub> and  $\Delta$ AUCglucose<sub>0-120</sub>. There is a significant correlation between  $\Delta$ AI and the variation of AUC insulin<sub>0-120</sub>, AUCglucose<sub>0-120</sub> and triglyceride. Finally,  $\Delta$ AP is significantly correlated with  $\Delta$ AUC insulin<sub>0-120</sub> and  $\Delta$ IGF-1. Thus, variables reaching statistical significance and gender, as dichotomic variable, were added in a stepwise multivariate linear regression model to assess the magnitude of their individual effect on  $\Delta$ PWV,  $\Delta$ AI and  $\Delta$ AP. The variation of AUC insulin<sub>0-120</sub> is the strongest predictor for all three vascular function parameters. In particular, it justifies a 30.9, 29.4 and 13.2% of variation

for  $\Delta$ PWV,  $\Delta$ AI and  $\Delta$ AP, respectively. The change in AUCglucose<sub>0-120</sub> adds another 6.7% for  $\Delta$ PWV variation and  $\Delta$ IGF-1 accounts for another 10.9% for  $\Delta$ AP.

### Discussion

In this study, we demonstrate that a 6-month treatment with an oral complex containing silybin, phosphatidylcholine and vitamin E induces, in a group of newly diagnosed hypertensive patients, a significant improvement in the metabolic and inflammatory profile. In particular, silybin treatment is able to reduce both fasting glucose and insulin levels as well as glucose and insulin AUC during OGTT, with the increase of the Matsuda index, confirming its positive impact on IR status. As a consequence of insulin sensitivity improvement, IGF-1 levels significantly increase while hs-CRP levels decrease. Clinically relevant, all these changes occur

**Table 3** Linear regression analysis on pulse wave velocity (PWV), augmentation index (AI) and augmentation pressure (AP) variation ( $\Delta_{T0-6}$ ) after 6 months of silybin treatment

	PWV ( $\Delta_{T0-6}$ )		AI ( $\Delta_{T0-6}$ )		AP( $\Delta_{T0-6}$ )	
	<i>R</i>	<i>P</i>	<i>R</i>	<i>P</i>	<i>R</i>	<i>P</i>
$\Delta$ AUC insulin <sub>0-120</sub>	0.556	<0.0001	0.542	<0.0001	0.364	0.005
$\Delta$ AUCglucose <sub>0-120</sub>	0.526	<0.0001	0.273	0.028	0.200	0.082
$\Delta$ Total cholesterol, mg/dl	0.150	0.149	0.218	0.064	0.049	0.367
$\Delta$ HDL-cholesterol, mg/dl	0.235	0.050	0.027	0.427	0.079	0.292
$\Delta$ Triglyceride, mg/dl	0.005	0.488	0.257	0.036	0.194	0.089
$\Delta$ Uric acid, mg/dl	0.010	0.474	− 0.004	0.489	0.209	0.072
$\Delta$ e-GFR, ml/min/1.73 m <sup>2</sup>	0.015	0.459	0.207	0.075	− 0.011	0.469
$\Delta$ hs-CRP, mg/L	0.135	0.174	− 0.058	0.344	− 0.137	0.171
$\Delta$ IGF-1, ng/ml	− 0.005	0.486	0.108	0.227	− 0.336	0.009
$\Delta$ central PP, mm/Hg	0.214	0.068	− 0.118	0.206	− 0.140	0.167

AUC area under the curve, PP pulse pressure, e-GFR estimated glomerular filtration rate, hs-CRP high-sensitivity C-reactive protein, ISI insulin sensitivity index, IGF-1 insulin like growth factor-1, PP pulse pressure

independently of the body weight modification; in fact, both BMI and waist circumference did not change significantly.

This study is the first evidence of the positive metabolic effects exerted by silybin, on NGT hypertensive patients with high 1-h post-load plasma glucose who are at high risk for incident type 2 diabetes and target organ damage [3–7]. In fact, in previous studies, the metabolic effects of silybin were assessed in patients with NAFLD, where silybin treatment was associated with a significant improvement of IR, liver function tests and liver histology [11, 12]. The positive effect of silybin on insulin signalling may be partly explained by the attenuation of the insulin receptor substrate-1 (IRS-1)/phosphoinositide 3-kinase (PI3K)/Akt pathway, as demonstrated by experimental *in vitro* and *in vivo* studies [10, 22, 23]. In particular, in skeletal muscle cells, silybin may prevent palmitate-induced IR promoting IRS-1 tyrosine phosphorylation, and inhibiting the negative effect of serine phosphorylation [22]. Moreover, in an NAFLD animal model, the addition of silybin improves IR and hepatic histology, while being able to reduce resistin expression in cultured rat liver cells. Similarly, in our patients, we also observe a significant reduction of both AST and ALT levels.

Because all these actions are able to be nullified by a PI-3K specific blocker, it is plausible that silybin operates by this pathway [23]. Thus, on this evidence, it is possible to affirm that the positive effects of silybin on IR pathophysiological mechanisms may be clinically relevant because the improvement of insulin sensitivity reduces the inflammatory burden and oxidative stress that promote different pathogenetic pathways, leading not only to glucose intolerance, but also in the development of subclinical target organ damage that represents an independent predictor of subsequent cardiovascular events [24–26].

At the same time, we also demonstrate a significant improvement of all the parameters related to vascular stiffness due to the reduction of AUC insulin<sub>0–120</sub> after silybin treatment, which is the strongest predictor of these changes, justifying in particular a 30.9% of PWV variation. These findings confer an important biological plausibility to our results, because an increase in PWV is associated with the rise in both central SBP and PP, with a consequent growth of cardiac systolic work and decrease of coronary perfusion pressure, all conditions promoting CV events [27, 28]. Apart from the improvement of IR, the positive effect of silybin on vascular stiffness may be justified by other mechanisms. In particular, silybin has demonstrated, in a mouse model of diabetes, reduced plasma and aorta asymmetric dimethyl-L-arginine levels [13], an endogenous competitive inhibitor of endothelial nitric oxide synthase that reduces nitric oxide bioavailability in humans [29]. In addition, silybin is able to inhibit radical accumulation by an important scavenger activity, interfering with both lipid membrane peroxidation

and stabilization of mitochondrial membrane [9, 30]. In particular, in rats with NAFLD, silybin treatment is more effective than that with rosiglitazone in increasing the levels of superoxide dismutase and glutathione. Moreover, silybin enhances the gene and protein expression of adiponectin, but inhibits that of resistin thus improving insulin sensitivity. Finally, silybin is effective in stabilizing mitochondrial membrane fluidity with reduction of free radicals [30]. Therefore, it is plausible that the positive effect on IR and mitochondrial function and the inhibition of oxidative stress may represent the crucial mechanisms for the vascular protective effect of silybin and these actions may justify the reduction of arterial stiffness as demonstrated in our study.

It is likely that the improvement of vascular compliance may justify the reduction of both SBP and PP as observed in our patients, conferring a clinical relevance because, as reported in a recent meta-analysis, including 123 studies with over 600,000 participants, a 10 mmHg reduction in SBP reduces the risk of major CV events by 20%, coronary heart disease by 17% and stroke by 27% [31]. The vascular benefit after treatment is also evidenced by the improvement in renal function as demonstrated by a significant reduction of creatinine and increase of e-GFR.

Obviously, this is a pilot study obtained on a small sample, and these data should be confirmed in a randomized controlled multicenter study, including a larger number of patients. In addition, the results were observed in NGT hypertensives with high 1-h post-load plasma glucose, and it may not be valid in other settings of patients. Another important limitation of the study is the lack of oxidative stress evaluation after intake of silybin. This is a crucial point because the reduction of oxidative stress may account for the improvement in arterial stiffness. However, the reduction of oxidative stress, even if not measured, can be hypothesized considering the betterment of insulin sensitivity and inflammatory burden observed in patients of the study after silybin intake.

Finally, the strengths are represented by the complete metabolic assessment. In fact, IR was assessed with OGTT-derived indices, considering glycemic and insulimic responses. Moreover, vascular stiffness was measured by carotid–femoral PWV that represents the gold standard test.

In conclusion, this study demonstrates that silybin may improve the metabolic aspect and vascular damage in NGT hypertensive patients with 1 h-post-load plasma glucose  $\geq 155$  mg/dl, characterized by higher metabolic and cardiovascular risk. Taken together, in hypertensive insulin-resistant patients, silybin might strengthen the effect of antihypertensive drugs through the improvement of the metabolic condition, giving further vascular protection.

## Compliance with ethical standards

**Conflict of interest** The authors declare that they have no conflict of interest.

**Statements on human and animal rights** All procedures performed in studies involving human participants were in accordance with the ethical standards of the institutional or national research committee and with the 1964 Helsinki Declaration and its later amendments or comparable ethical standards.

**Informed consent** Informed consent was obtained from all individual participants included in the study.

## References

- Ferrannini E, Cushman WC (2012) Diabetes and hypertension: the bad companions. *Lancet* 380:601–610. [https://doi.org/10.1016/S0140-6736\(12\)60987-8](https://doi.org/10.1016/S0140-6736(12)60987-8)
- Muniyappa R, Montagnani M, Koh KK, Quon MJ (2007) Cardiovascular actions of insulin. *Endocr Rev* 28:463–491. <https://doi.org/10.1210/er.2007-0006>
- Fiorentino TV, Marini MA, Andreozzi F, Arturi F, Succurro E, Perticone M, Sciacqua A, Hribal ML, Perticone F, Sesti G (2015) One-hour post load hyperglycemia is a stronger predictor of type 2 diabetes than impaired fasting glucose. *J Clin Endocrinol Metab* 100:3744–3751. <https://doi.org/10.1210/jc.2015-2573>
- Sciacqua A, Miceli S, Carullo G, Greco L, Succurro E, Arturi F, Sesti G, Perticone F (2011) One-hour post load plasma glucose levels and left ventricular mass in hypertensive patients. *Diabetes Care* 34:1–6. <https://doi.org/10.2337/dc11-0155>
- Sciacqua A, Miceli S, Greco L, Arturi F, Naccarato P, Mazzaferro D, Tassone EJ, Turano L, Martino F, Sesti G, Perticone F (2011) One-hour postload plasma glucose levels and diastolic function in hypertensive patients. *Diabetes Care* 34:2291–2296. <https://doi.org/10.2337/dc11-0879>
- Sciacqua A, Maio R, Miceli S, Pascale A, Carullo G, Grillo N, Arturi F, Sesti G, Perticone F (2012) Association between one-hour post-load plasma glucose levels and vascular stiffness in essential hypertension. *PLoS One* 7:e44470. <https://doi.org/10.1371/journal.pone.0044470>
- Perticone F, Sciacqua A, Perticone M, Miceli S, Maio R, Tassone JE, Arturi F, Sesti G (2013) Phenotypic characterization of normotolerant hypertensive patients. *Int J Cardiol* 165:322–326. <https://doi.org/10.1016/j.ijcard.2011.08.076>
- Perticone F, Sciacqua A, Perticone M, Arturi F, Scarpino PE, Quero M, Sesti G (2012) *Diabetes Care* 35:153–157. <https://doi.org/10.2337/dc11-1727>
- Loguercio C, Festi D (2011) Silybin and the liver: from basic research to clinical practice. *World J Gastroenterol* 17:2288–2301. <https://doi.org/10.3748/wjg.v17.i18.2288>
- Trappolieri M, Caligiuri A, Schmid M, Bertolani C, Failli P, Vizzutti F, Novo E, di Manzano C, Marra F, Loguercio C, Pinzani M (2009) Silybin, a component of silymarin, exerts anti-inflammatory and anti-fibrogenic effects on human hepatic stellate cells. *J Hepatol* 50:1102–1111. <https://doi.org/10.1016/j.jhep.2009.02.023>
- Federico A, Trappolieri M, Tuccillo C, de Sio I, Di Leva A, Del Vecchio Blanco C, Loguercio C (2006) A new silybin–vitamin E–phospholipid complex improves insulin resistance and liver damage in patients with non-alcoholic fatty liver disease: preliminary observations. *Gut* 55:901–902. <https://doi.org/10.1136/gut.2006.091967>
- Loguercio C, Andreone P, Brisc C, Brisc MC, Bugianesi E, Chiaromonte M, Cursaro C, Danila M, de Sio I, Floreani A, Freni MA, Grieco A, Groppo M, Lazzari R, Lobello S, Loreface E, Margotti M, Miele L, Milani S, Okolicsanyi L, Palasciano G, Portincasa P, Saltarelli P, Smedile A, Somalvico F, Spadaro A, Sporea I, Sorrentino P, Vecchione R, Tuccillo C, Del Vecchio Blanco C, Federico A (2012) Silybin combined with phosphatidylcholine and vitamin E in patients with nonalcoholic fatty liver disease: a randomized controlled trial. *Free Radic Biol Med* 52:1658–1665. <https://doi.org/10.1016/j.freeradbiomed.2012.02.008>
- Li Volti G, Salomone S, Sorrenti V, Mangiameli A, Urso V, Siarkos I, Galvano F, Salamone F (2011) Effect of silybinin on endothelial dysfunction and ADMA levels in obese diabetic mice. *Cardiovasc Diabetol*. 10:62. <https://doi.org/10.1186/1475-2840-10-62>
- Matsuda M, DeFronzo RA (1999) Insulin sensitivity indices obtained from oral glucose tolerance testing: comparison with the euglycemic insulin clamp. *Diabetes Care* 22:1462–1470
- Abdul-Ghani MA, Matsuda M, Balas B, DeFronzo RA (2007) Muscle and liver insulin resistance indexes derived from the oral glucose tolerance test. *Diabetes Care* 30:89–94. <https://doi.org/10.2337/dc06-1519>
- Le Floch JP, Escuyer P, Baudin E, Baudon D, Perlemuter L (1990) Blood glucose area under the curve, methodological aspects. *Diabetes Care* 13:172–175
- Levey AS, Stevens LA, Schmid CH, Zhang YL, Castro AF 3rd, Feldman HI, Kusek JW, Eggers P, Van Lente F, Greene T, Coresh J, CKD-EPI (Chronic Kidney Disease Epidemiology Collaboration) (2009) A new equation to estimate glomerular filtration rate. *Ann Intern Med* 150:604–612
- ESH/ESC guidelines for the management of arterial hypertension (2013) The task force for the management of arterial hypertension of the European Society of Hypertension (ESH) and of the European Society of Cardiology (ESC). *Eur Heart J* 34:2159–2219. <https://doi.org/10.1093/eurheartj/eh151>
- Chen CH, Ting CT, Nussbacher A, Nevo E, Kass DA, Pak P, Wang SP, Chang MS, Yin FC (1996) Validation of carotid artery tonometry as a means of estimating augmentation index of ascending aortic pressure. *Hypertension* 27:168–175
- European Guidelines on cardiovascular disease prevention in clinical practice (2016) The sixth joint task force of the European Society of Cardiology and Other Societies on Cardiovascular Disease Prevention in Clinical Practice (constituted by representatives of 10 societies and by invited experts) Developed with the special contribution of the European Association for Cardiovascular Prevention & Rehabilitation (EA). *Eur Heart J* 37:2315–2381
- Bolignano D, Mattace-Raso F, Torino C, D'Arrigo G, Abd ElHafeez S, Provenzano F, Zoccali C, Tripepi G (2013) The quality of reporting in clinical research: the CONSORT and STROBE initiatives. *Aging Clin Exp Res* 25:9–15. <https://doi.org/10.1007/s40520-013-007-z>
- Li HB, Yang YR, Mo ZJ, Ding Y, Jiang WJ (2015) Silybinin improves palmitate-induced insulin resistance in C2C12 myotubes by attenuating IRS-1/PI3 K/Akt pathway inhibition. *Braz J Med Biol Res* 48:440–446. <https://doi.org/10.1590/1414-431X20144238>
- Zhang Y, Hai J, Cao M, Zhang Y, Pei S, Wang J, Zhang Q (2013) Silybinin ameliorates steatosis and insulin resistance during non-alcoholic fatty liver disease development partly through targeting IRS-1/PI3K/Akt pathway. *Int Immunopharmacol* 17:714–720. <https://doi.org/10.1016/j.intimp.2013.08.019>
- Ceravolo R, Maio R, Cuda G, Scozzafava A, Sciacqua A, Vatrano M, Bellieni G, D'Angelo G, Schipani FA, Sesti G, Perticone F (2003) Relation of fasting insulin related to insertion/deletion polymorphism of angiotensin-converting enzyme-gene and cardiac mass in never-treated patients with systemic hypertension. *Am J Cardiol* 92:1234–1237

25. Nerpin E, Riséru U, Ingelsson E, Sundström J, Jobs M, Larsson A, Basu S, Arnlöv J (2008) Insulin sensitivity measured with euglycemic clamp is independently associated with glomerular filtration rate in a community-based cohort. *Diabetes Care* 31:1550–1555. <https://doi.org/10.2337/dc08-0369>
26. Sciacqua A, Scozzafava A, Pujia A, Maio R, Borrello F, Andreozzi F, Vatrano M, Cassano S, Perticone M, Sesti G, Perticone F (2005) Interaction between vascular dysfunction and cardiac mass increases the risk of cardiovascular outcomes in essential hypertension. *Eur Heart J* 26:921–927. <https://doi.org/10.1093/eurheartj/ehi112>
27. Avolio AP, Van Bortel LM, Boutouyrie P, Cockcroft JR, McEniery CM, Protogerou AD, Roman MJ, Safar ME, Segers P, Smulyan H (2009) Role of pulse pressure amplification in arterial hypertension: experts' opinion and review of the data. *Hypertension* 54:375–383. <https://doi.org/10.1161/HYPERTENSIONAHA.109.134379>
28. Ceravolo R, Maio R, Pujia A, Sciacqua A, Ventura G, Costa MC, Sesti G, Perticone F (2003) Pulse pressure and endothelial dysfunction in never-treated hypertensive patients. *J Am Coll Cardiol* 41:1753–1758
29. Perticone F, Sciacqua A, Maio R, Perticone M, Maas R, Boger RH, Tripepi G, Sesti G, Zoccali C (2005) Asymmetric dimethylarginine, L-arginine, and endothelial dysfunction in essential hypertension. *J Am Coll Cardiol* 46:518–523. <https://doi.org/10.1016/j.jacc.2005.04.040>
30. Yao J, Zhi M, Minhu C (2011) Effect of silybin on high-fat-induced fatty liver in rats. *Braz J Med Biol Res* 44:652–659
31. Ettehad D, Emdin CA, Kiran A, Anderson SG, Callender T, Emberson J, Chalmers J, Rodgers A, Rahimi K (2016) Blood pressure lowering for prevention of cardiovascular disease and death: a systematic review and meta-analysis. *Lancet* 387:957–967. [https://doi.org/10.1016/S0140-6736\(15\)01225-8](https://doi.org/10.1016/S0140-6736(15)01225-8)